Select baseline demographic and disease characteristics
| Characteristic* | All patients with I/P risk13 | Patients with I/P-risk sRCC9 | ||
| NIVO+IPI | SUN | NIVO+IPI | SUN | |
| (N=425) | (N=422) | (n=74) | (n=65) | |
| Median age (range), years | 62 (26–85) | 61 (21–85) | 58 (35–84) | 61 (39–79) |
| Sex, n (%) | ||||
| Male | 314 (74) | 301 (71) | 55 (74) | 48 (74) |
| Female | 111 (26) | 121 (29) | 19 (26) | 17 (26) |
| IMDC prognostic score, n (%) | ||||
| Intermediate (1–2) | 334 (79) | 333 (79) | 54 (73) | 48 (74) |
| Poor (3–6) | 91 (21) | 89 (21) | 20 (27) | 17 (26) |
| Region, n (%) | ||||
| USA | 112 (26) | 111 (26) | 34 (46) | 19 (29) |
| Canada/Europe | 148 (35) | 146 (35) | 20 (27) | 29 (45) |
| Rest of the world | 165 (39) | 165 (39) | 20 (27) | 17 (26) |
| Prior nephrectomy, n (%) | 341 (80) | 319 (76) | 66 (89) | 54 (83) |
| No of sites with target/nontarget lesions,† n (%) | ||||
| 1 | 90 (21) | 84 (20) | 15 (20) | 16 (25) |
| ≥2 | 335 (79) | 337 (80) | 59 (80) | 49 (75) |
| Most common sites of metastasis,ठn (%) | ||||
| Lung | 294 (69) | 296 (70) | 58 (78) | 50 (77) |
| Lymph node | 190 (45) | 216 (51) | 36 (49) | 36 (55) |
| Bone¶ | 95 (22) | 97 (23) | 16 (22) | 13 (20) |
| Liver | 88 (21) | 89 (21) | 10 (14) | 8 (12) |
| Quantifiable tumor PD-L1 expression, n (%) | n=384 | n=392 | n=71 | n=62 |
| <1% | 284 (74) | 278 (71) | 35 (49) | 29 (47) |
| ≥1% | 100 (26) | 114 (29) | 36 (51) | 33 (53) |
*Information shown in the table is based on data collected with the use of an interactive voice-response system.
†The number of target or nontarget lesions at baseline was not reported for one patient in the SUN group.
‡Patients may have lesions at more than one site.
§Includes both target and nontarget lesions.
¶Includes bone with and without a soft-tissue component.
IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; I/P, intermediate/poor; NIVO+IPI, nivolumab plus ipilimumab; PD-L1, programmed death ligand 1; sRCC, sarcomatoid renal cell carcinoma; SUN, sunitinib.